Participants

Paul Voigt; Interim Chief Executive Officer; Innovate Corp

Michael Sena; Chief Financial Officer; Innovate Corp

Presentation

Operator

Good afternoon and welcome to elevate Corp's first quarter 2024 earnings conference call. All participants will be in a listen only mode after their prepared remarks and presentation, there will be a question and answer session. Please note this event is being recorded, and I would like to turn the conference call over to Mr. [Neil Seika] with Investor Relations. Please go ahead.

Good afternoon. Thank you for being with us to review innovates First Quarter 2020 for earnings results. We are joined today by Paul Beesley, innovates Interim CEO and Mike center, innovate, CFO. We have posted our earnings release and our slide presentation on our website at avistacorp.com. We will begin our call with prepared remarks to be followed by a Q&A session. This call is also being simulcast and will be archived on our website.
During this call, management may make certain statements and assumptions which are not historical facts. It will be forward-looking and are being made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risks assumptions and uncertainties and are subject to certain assumptions and risk factors that could cause its actual results to differ materially from these forward-looking statements.
The risk factors that could cause these differences are more fully discussed in the cautionary statement that is included in our earnings release and the slide presentation and further detailed in our 10-K and other filings with the SEC.
In addition, the forward-looking statements included in this conference call are only made as of the date of this call. And as stated in our SEC reports, NOV disclaims any intent or obligation to update or revise these forward-looking statements, except as expressly required by law, Management will also refer to certain non-GAAP financial measures such as adjusted EBITDA. We believe that these measures provide useful supplemental data that while not a substitute for GAAP measures allow for greater transparency in the review of our financial and operational performance.
At this point, it is my pleasure to turn things over to Paul Boyd.

Paul Voigt

Good afternoon. We had a great start to the first quarter of 2024 by achieving strong operational and financial results. Innovate delivered revenues of $315.2 million and adjusted EBITDA of $12.8 million in the first quarter of 2024. Rustin and his team at DBM Global delivered another strong quarter with revenues of $307.9 million and adjusted EBITDA of $18.3 million, while top line results were relatively flat compared to a year ago, we experienced strong year-over-year adjusted EBITDA growth, which was driven by significant gross margin expansion, up approximately 150 basis points to 14.6%. Adjusted EBITDA margin also expanded year-over-year by approximately 70 basis points to 5.9% in the first quarter.
DBM.'s total adjusted backlog, which takes into consideration awarded but not yet signed contracts remains at a healthy level of 1.2 billion at the end of the first quarter. Overall, the commercial construction sectors of the market continue to be very tight although the bidding activity remains at high levels. However, we are seeing numerous opportunities both in industrial and modularization sectors of the market. This surge in new work activity will be a meaningful piece of our business in 2024 and beyond.
Moving on to Life Sciences, Dave and Srini and the R. two team had another exciting quarter and continues to gain traction with yet another record-breaking increase in North American system sales growth of 183% as compared to the prior year quarter are to achieve to record high system sales in a single quarter in North America for the second quarter in a row, our team has continued to grow outside of North America by launching their product in the Middle East during the quarter.
Our two continued growth in other areas of the business experiencing a 115% increase in patients treated and 47% increase in average monthly utilization per glacial provider from the same period of last year with a continued focus on market awareness initiatives. Our two experienced increases across the board from social media mentions and followers to website traffic. As these are clear indicators of qualified buyer interest, it is important to note that these initiatives have led to a significant increase in system sales opportunities in 2024.
We are encouraged by the momentum our two is beginning to build in the market as we continue to see expanded use and demand of their state of the art technology, and this momentum has continued into the second quarter and MediBeacon. The Company continues to work through their substantive review for kidney monitoring program with the FDA as previously explained MediBeacon met with the FDA in the first and second quarters of 2024 and is working interactively to resolve outstanding questions in order to move to approval status, we hope to provide an update on MediBeacon process. As mentioned on our last call, MediBeacon pivotal study results were posted on the clinicaltrials.gov website on April 18th.
As noted on the clinicaltrials.gov website, MediBeacon transdermal GFR measurement system met the predetermined primary and secondary endpoints established with the FDA prior to starting the study, we see great opportunity in the market for real-time monitoring of kidney function. And we have seen a number of recent studies and trends in the market impact ash, chronic kidney disease or the acronym DKD. study forecasts that up to 16.5% of the population across eight countries will suffer from CKD. by 2032. Astrazeneca sponsored and recently presented this study at the World Congress of Nephrology, the reveal that CK. study concluded that a record CKD. diagnosis was associated with significant improvements in CKD management and monitoring pharmaceutical companies.
Are increasing investments in nephrology with a robust R&D pipeline that targets a range of kidney disease indications. It is estimated that there are approximately 500 pharmaceutical assets ranging from early development approved therapeutics that target chronic kidney disease indications. We see a number of factors, including the growth of GLP. dash one agnostics like Zenefits that are likely to positive would positively impact the growing addressable market for products that would provide an accurate and clinically practical assessment of kidney function.
Les and team at Spectrum delivered with a strong quarter and grew EBITDA to $1.6 million in the first quarter. Of note, the new 2024 network launches are driving higher revenue growth beginning with free TV January first network launches of 365 and the outlaw and subsequent launch of three new sports networks, outdoor America, Motor Sports one and speed sports TV network distribution revenues are growing as churn rates decline with existing network customers. Pricing has held and new programmers emerge, particularly for cable and streaming networks.
Looking for over the air coverage and in April, Spectrum participated in the NAB conference in Las Vegas, which generated considerable interest in HC2 Broadcasting's, robust national distribution platform from content providers and broadcasters. At the conference, we announced the operating and revenue share agreements with large market public broadcast stations to provide three Datto light housing and commercial applications.
And given our continued efforts in exploring revenue opportunities for repurpose broadcast spectrum with new technology we continue to work closely with Qualcomm, the technology leader in 5G broadcasting as well as other strategic, including equipment vendors of 5G broadcasting. We believe our efforts in alternative technologies like ATSC 3.0 and 5G broadcasting will offer opportunities to optimize future revenues. We are very happy with the operational results of all three of our segments as DBN. continues to perform at high levels with a robust product pipeline, encouraging growth and momentum at our two progress at MediBeacon on FDA approval and an increase in OTA demand combined with next-gen opportunities continue to develop.
We continue to be highly focused on addressing our capital structure, which we believe is the key driver in the underperformance of our stock price. We have now closed on our rights offering. And combined with our expectation of upstream cash payments from our subsidiaries, we believe we have created sufficient runway to execute on a strategy to utilize our non cash flowing assets to address our capital structure and set the company up to refinance our debt in 2024.
To that end, we continue to make progress exploring opportunities for our non cash flowing businesses. Our focus remains on being patient within the timeframe we have created to ensure that we maximize the value of these assets exiting these businesses for the right value takes time. We continue to be optimistic on the overall M&A market and hope to reach a resolution in 2024 as we continue to see positive indicators in the market, along with continued progress and momentum surrounding these assets. As discussed above, we look to build off this momentum in the second quarter and the remainder of the year.
With that, I'll turn it over to Mike for a review of our financial and capital structure.

Michael Sena

As for consolidated, total revenue for the first quarter of 2024 was $315.2 million, a decrease of 0.8% compared to $317.9 million in the prior year period. The decrease was primarily driven by our Infrastructure segment, which was partially offset by increases in our spectrum and life sciences segments.
Net loss attributable to common stockholders for the first quarter of 2024 or $17.7 million or $0.22 per share compared to a net loss of $10.2 million or $0.13 per share in the prior year period. Total adjusted EBITDA was $12.8 million in the first quarter of 2024, an increase from $4.9 million in the prior year period. The increase was driven by all of our segments. And infrastructure, revenue decreased 1.2% to $307.9 million from $311.7 million in the prior year quarter. This decrease was primarily driven by the timing and size of projects at DBMG.'s commercial steel fabrication and erection business and Banker Steel which was partially offset by an increase in revenue at the industrial maintenance and repair business due to timing and size of projects.
Infrastructure.
Adjusted EBITDA for the first quarter of 2024 increased to $18.3 million from $16.3 million in the prior year period. The increase was driven by higher margins at CBMG.'s commercial structural steel fabrication and erection and the industrial maintenance and repair businesses, which was partially offset by an increase in recurring SG&A, primarily primarily as a result of compensation related expenses as well as a decrease in margin with the construction modeling and detailing business as of March 31st, 2024, and in line with our expectation, reported backlog was $939.1 million. And adjusted backlog, which takes into consideration awarded but not yet signed contracts, was $1.2 billion compared to reported backlog of $1.1 billion and adjusted backlog of $1.2 billion at the end of 2023. DBMG. ended the quarter with $159.7 million in principal amount of debt, which is a decrease of $39.1 million from year end to 2023, primarily driven by the reduction of the credit facility and normal debt amortization payments.
CBMG. has been able to reduce its debt obligations through line reduction as invest in working capital has continued to return to the business, a trend that began at the end of 2023. As backlog stabilizes, we expect flat working capital needs throughout 2024. As a reminder, CBMG. has reduced its outstanding debt by approximately 73 million in the last six months.
At Life Sciences revenue was $1 million, an increase of $0.5 million from the prior year quarter. The increase in revenue was attributable to our two primarily due to growth in unit sales in North America. Life Sciences adjusted EBITDA losses decreased for the quarter, which was primarily due to lower equity method losses recognized from our investment in MediBeacon and to a lesser extent, a decrease in SG&A expenses at R2 as well as an increase in revenue, primarily due to an increase in unit sales. At spectrum revenue was $6.3 million, an increase of $0.6 million compared to the first quarter of 2023, primarily driven by the launch new networks and expanded coverage with existing customers. Increase was partially offset by the termination of a number of smaller networks and individual markets subsequent to the comparable period.
Spectrum reported adjusted EBITDA in the first quarter increased to $1.6 million from $0.4 million in the prior year quarter. The increase was primarily due to the increase in revenue and the impact of the personnel realignment implemented in the second half of 2023. Nonoperating corporate adjusted EBITDA losses were $2.9 million for the quarter of 2024, an improvement from the first quarter of 2023 of $0.6 million improvement was primarily driven by decreases in compensation related expenses, consulting fees and insurance expense, which was partially offset by an increase in legal fees.
At the end of the first quarter, the Company had $38.4 million of cash and cash equivalents, excluding restricted cash, compared to $80.8 million as of December 31st, 2023. On a stand-alone basis as of March 31st, 2024 a non-operating corporate segment at cash and cash equivalents of $9.2 million compared to $2.5 million at the end of '23.
As announced earlier in the year, we received notice that we are not in compliance with NYSE listing requirements as our stock price. It has fallen below $1 per share. We are working on options to regain compliance with the NYSE, which includes the potential for a reverse stock split as disclosed in our recently filed proxy statement. As of March 31st, 2024, innovate had total principal outstanding indebtedness of $687 million, down $35.8 million from $722.8 billion at the end of 2023, driven by the decrease of infrastructures outstanding debt, which was partially offset by our team's extension of financial capital, which capitalized interest payments into the principal balance.
With that, operator, we'd now like to open up the call for questions.

Question and Answer Session

Operator

(Operator Instructions) No questions at this time. I will turn the call back over Paul.

Paul Voigt

Yes, I appreciate everybody's time and support and patience and look forward to coming back to everybody with some positive news over the next quarter or two. Thank you for your time.

Operator

Ladies and gentlemen, this concludes today's conference call. You may now disconnect.